ArticleLeukemia2017

Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia.

S Eldfors et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.